16 September 2026 editorial review · Item
Diabeloop DBLG2: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Final link check: replaced the obsolete Sequel announcement path with the matching official 13 January 2026 release. This is a URL repair, not evidence that the planned pairing has launched.
Record: Diabeloop DBLG2
Scope and findings:
- Read July10 official prescription launch: Germany, Android, Kaleido/G7. Current Kaleido site still says Netherlands later2026, so earlier summer target is not proof of launch. iOS remains future; older DBLG1 outcomes do not directly validate DBLG2.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.
Thriving evidence review — 16 September 2026
Additional ranking review, 16 September 2026. Checked outcome attribution, generation differences, cohort comparability and criterion rationale against primary sources. Corrected false claims and added measured/provisional distinctions. Full findings and source-specific limits are in the AID ranking evidence audit. Numerical ratings were left to the central scoring calibration.